IsoRay, Inc. (NYSEAMERICAN:ISR) was the recipient of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 100,258 shares, a decrease of 35.2% from the May 15th total of 154,774 shares. Based on an average daily volume of 361,924 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are short sold.
Shares of IsoRay opened at $0.46 on Thursday, Marketbeat Ratings reports. IsoRay has a fifty-two week low of $0.36 and a fifty-two week high of $0.64.
IsoRay (NYSEAMERICAN:ISR) last issued its quarterly earnings results on Thursday, May 3rd. The healthcare company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%. The firm had revenue of $1.57 million during the quarter.
A number of analysts have weighed in on the stock. Ascendiant Capital Markets assumed coverage on shares of IsoRay in a report on Monday, April 2nd. They issued a “buy” rating and a $1.00 price target for the company. Maxim Group set a $2.00 price target on shares of IsoRay and gave the company a “buy” rating in a report on Friday, May 4th.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.